1. Home
  2. HOUR vs IVVD Comparison

HOUR vs IVVD Comparison

Compare HOUR & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hour Loop Inc.

HOUR

Hour Loop Inc.

HOLD

Current Price

$2.05

Market Cap

69.3M

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$2.39

Market Cap

692.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOUR
IVVD
Founded
2015
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.3M
692.7M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
HOUR
IVVD
Price
$2.05
$2.39
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.33
AVG Volume (30 Days)
106.3K
12.0M
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$140,790,433.00
$50,039,000.00
Revenue This Year
N/A
$103.88
Revenue Next Year
N/A
$171.40
P/E Ratio
$85.48
N/A
Revenue Growth
N/A
332.71
52 Week Low
$1.10
$0.35
52 Week High
$6.90
$3.07

Technical Indicators

Market Signals
Indicator
HOUR
IVVD
Relative Strength Index (RSI) 47.62 57.18
Support Level $2.01 $2.15
Resistance Level $2.24 $2.60
Average True Range (ATR) 0.11 0.19
MACD 0.03 -0.03
Stochastic Oscillator 53.13 48.36

Price Performance

Historical Comparison
HOUR
IVVD

About HOUR Hour Loop Inc.

Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: